We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-6.2%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.77B
AUM Growth
-$356M
Cap. Flow
-$1.35B
Cap. Flow %
-28.26%
Top 10 Hldgs %
39.93%
Holding
155
New
23
Increased
16
Reduced
21
Closed
28

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$89.6M
2
AHCO icon
AdaptHealth
AHCO
+$49.8M
3
ESPR
Esperion Therapeutics
ESPR
+$40M
4
XLO icon
Xilio Therapeutics
XLO
+$36.7M
5
FIGS icon
FIGS
FIGS
+$27.3M

Top Sells

Rank Stock Value
1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$30.8M
2
MOH icon
Molina Healthcare
MOH
+$28.8M
3
CYTK icon
Cytokinetics
CYTK
+$28.1M
4
XLRN
Acceleron Pharma
XLRN
+$25M
5
FATE icon
Fate Therapeutics
FATE
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 62.96%
2 Financials 1.4%
3 Consumer Discretionary 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
51
DELISTED
KalVista Pharmaceuticals
KALV
$15.5M 0.33%
1,175,131
-988,423
-46% -$15.7M
APEN
52
DELISTED
Apollo Endosurgery, Inc.
APEN
$14.8M 0.31%
+1,750,000
New +$15.3M
VINC
53
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$14.1M 0.29%
68,966
– –
MRUS
54
DELISTED
Merus
MRUS
$13.9M 0.29%
+437,000
New +$12.3M
COGT icon
55
Cogent Biosciences
COGT
$6.91B
$13.7M 0.29%
1,601,000
– –
MRTX
56
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.9M 0.27%
+88,000
New +$13.7M
SRPT icon
57
Sarepta Therapeutics
SRPT
$1.68B
$12.7M 0.27%
+141,000
New +$12.1M
PMVP icon
58
PMV Pharmaceuticals
PMVP
$62.9M
$12.1M 0.25%
522,000
-282,000
-35% -$6.81M
BPMC
59
DELISTED
Blueprint Medicines
BPMC
$11.8M 0.25%
110,000
-75,354
-41% -$7.88M
HOWL icon
60
Werewolf Therapeutics
HOWL
$22M
$11.4M 0.24%
958,125
-794,662
-45% -$12M
QSI icon
61
Quantum-Si Incorporated
QSI
$171M
$11M 0.23%
1,400,000
– –
LIAN
62
DELISTED
LianBio American Depositary Shares
LIAN
$11M 0.23%
+1,782,747
New +$20.4M
NYXH
63
Nyxoah
NYXH
$140M
$10.5M 0.22%
455,262
+154,462
+51% +$3.55M
CGEM icon
64
Cullinan Oncology
CGEM
$1.07B
$10.4M 0.22%
671,690
-372,310
-36% -$7.43M
TLSI icon
65
TriSalus Life Sciences
TLSI
$265M
$9.88M 0.21%
999,999
– –
SRSA
66
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
$9.79M 0.21%
+999,999
New +$9.84M
EUCR
67
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$9.76M 0.2%
+999,999
New +$9.8M
SNRH
68
DELISTED
Senior Connect Acquisition Corp. I Class A Common Stock
SNRH
$9.74M 0.2%
1,000,000
– –
REVH
69
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock
REVH
$9.74M 0.2%
1,000,000
– –
CALC icon
70
CalciMedica
CALC
$11.1M
$9.67M 0.2%
377,265
– –
ORTX
71
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$9.17M 0.19%
694,942
– –
AFIB
72
DELISTED
Acutus Medical Inc
AFIB
$9.03M 0.19%
2,648,386
– –
WEAV icon
73
Weave Communications
WEAV
$529M
$8.42M 0.18%
+554,519
New +$9.32M
PRVA icon
74
Privia Health
PRVA
$3.11B
$7.76M 0.16%
300,000
– –
TMPM
75
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$7.37M 0.15%
+750,000
New +$7.35M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2021 Portfolio in Review

As of Q4 2021, Deerfield Management held 155 positions worth $4.77B, down 7% from $5.12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Deerfield Management withdrew a net $1.35B in Q4 2021, closing 28 positions and reducing 21 holdings. Its most notable exit was Acceleron Pharma, an estimated $25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 66% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Esperion Therapeutics worth $25M.

  • Deerfield Management's largest Q4 2021 buy was Esperion Therapeutics: 5,000,000 shares worth $25M.
  • Deerfield Management added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021, an estimated $89.6M increase.
  • Deerfield Management's biggest Q4 2021 reduction was BioDelivery Sciences International, Inc., cutting an estimated $30.8M.
  • Deerfield Management fully exited Acceleron Pharma in Q4 2021, selling an estimated $25M.
  • Deerfield Management's ten largest holdings make up 40% of its $4.77B portfolio in Q4 2021.
  • Deerfield Management opened 23 new positions and closed 28 in Q4 2021.
  • Deerfield Management's portfolio value fell 7% quarter-over-quarter to $4.77B.

Based on Deerfield Management's 13F filing for Q4 2021, filed 14 Feb 2022.